⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL529657 | 0.92 | — | — | |
| SCHEMBL7804781 | 0.89 | — | — | |
| SCHEMBL1220128 | 0.89 | — | — | |
| SCHEMBL12985512 | 0.69 | — | — | |
| SCHEMBL8729 | 0.64 | — | — | |
| SCHEMBL3950444 | 0.64 | — | — | |
| SCHEMBL20055717 | 0.64 | HSD17B10 (0.42) | — | |
| SCHEMBL10919927 | 0.62 | — | — | |
| SCHEMBL1661685 | 0.62 | — | — | |
| SCHEMBL529246 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357255-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2023-11-09 | — | — | US | disclosed |
| US-11673894-B2 | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2023-06-13 | — | — | US | disclosed |
| US-20210139485-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2021-05-13 | — | — | US | disclosed |
| CN-112384515-A | Imidazopyrimidines and triazolopyrimidines as A2A/A2B inhibitors | 因赛特公司 | 2021-02-19 | — | — | CN | disclosed |
| EP-3759112-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | Incyte Corporation (US) | 2021-01-06 | — | — | EP | disclosed |
| US-20190292188-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2019-09-26 | — | — | US | disclosed |
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-22 | — | — | US | disclosed |
| WO-2009093009-A1 | FUSED TRICYCLIC THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-07-30 | — | — | WO | disclosed |
| WO-2006038001-A1 | AMINOPYRIMIDINE DERIVATIVES AS JNK INHIBITORS | CELLTECH R & D LIMITED (GB) | 2006-04-13 | — | — | WO | disclosed |
| EP-0773222-B1 | CARBAPENEM DERIVATIVE | EISAI CO LTD (JP) | 2001-10-04 | — | — | EP | disclosed |
| US-6037341-A | HAVING POTENT ANTIMICROBIAL EFFECTS OVER GRAM-POSITIVE BACTERIA AND GRAM-NEGATIVE BACTERIA | EISAI CO., LTD. (JP) | 2000-03-14 | — | — | US | disclosed |
| EP-0773222-A1 | NOVEL CARBAPENEM DERIVATIVE | Eisai Co., Ltd. (JP) | 1997-05-14 | — | — | EP | disclosed |